So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and Ultomiris (ravulizumab) – which are dosed by intravenous infusion every two and ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

In a landscape where access is no longer an after-thought, but a strategic imperative, this summit tackles the full lifecycle ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...